|
|
ORIGINAL ARTICLE |
|
Year : 2020 | Volume
: 27
| Issue : 1 | Page : 58-62 |
|
Radiotherapy treatment of spinal metastases in Ibadan: A 9-year review
Abbas Adesina Abdus-Salam1, Adeniyi Adedayo Olabumuyi2, Ajibike Ayomide Orekoya2, Mutiu Alani Jimoh1
1 Department of Radiation Oncology, University of Ibadan, Ibadan, Nigeria 2 Department of Radiation Oncology, University College Hospital, Ibadan, Nigeria
Date of Submission | 14-Mar-2019 |
Date of Acceptance | 21-Dec-2019 |
Date of Web Publication | 13-Mar-2020 |
Correspondence Address: Dr. Adeniyi Adedayo Olabumuyi Department of Radiation Oncology, University College Hospital, Ibadan Nigeria
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/wajr.wajr_8_19
Background: Metastatic spinal tumors signify disease progression and result in poor quality of life of patients. We are likely to see an increasing burden of spinal metastases due to the global trend of increasing cancer survival. Objective: The objective of this study was to review the pattern of presentation and radiotherapy of metastatic spinal tumors in the Radiation Oncology Department, University College Hospital, Ibadan, Nigeria. Materials and Methods: The radiation therapy records of all patients who received spinal irradiation between January 2007 and December 2015 were retrieved. The extracted data are patients' sociodemographic, clinicopathologic, and treatment factors which include the radiation dose given and retreatment dose. Results: Majority (91.7%) of the patients who had radiotherapy to the spine had metastatic spinal tumors. Male patients accounted for 69.1% of the cases and females accounted for 30.1% resulting in a male–female ratio of 2.23:1. Close to half (45.8%) of the patients were elderly. Prostate cancer (57.3%) and breast cancer (18.8%) were the most common primary sites. The most common involved spinal site was the thoracic region. In all age groups, fewer patients received a short radiotherapy treatment course (totaling 15 Gy or less and within a duration of 1 week) versus long radiotherapy treatment course (other radiation schedules not meeting criteria for short). Conclusion: A high index of suspicion of metastatic spinal cancer is required, particularly for breast and prostate cancers. The authors recommend that more elderly patients should be treated with short-course radiotherapy.
Keywords: Oncology, radiation oncology, spinal metastases
How to cite this article: Abdus-Salam AA, Olabumuyi AA, Orekoya AA, Jimoh MA. Radiotherapy treatment of spinal metastases in Ibadan: A 9-year review. West Afr J Radiol 2020;27:58-62 |
How to cite this URL: Abdus-Salam AA, Olabumuyi AA, Orekoya AA, Jimoh MA. Radiotherapy treatment of spinal metastases in Ibadan: A 9-year review. West Afr J Radiol [serial online] 2020 [cited 2023 Feb 4];27:58-62. Available from: https://www.wajradiology.org/text.asp?2020/27/1/58/280610 |
Introduction | |  |
Metastatic spinal tumors have a unique implication in an oncological practice. Not only do they signify disease progression, but also they have grave implications on the management of the patients. This is due to the fact that metastatic spinal tumors can lead to mechanical instability of the spine and neurological deficits.[1] These can affect the performance status and quality of life of the patient.
In Nigeria, the cancers with the highest prevalence are breast cancer, cervical cancer, and prostate cancer, with age-standardized prevalence rates of 185, 75.3, and 64.8 per 100,000, respectively.[2] These cancers, excluding cervical cancer, are known to be the most frequent types of cancer that metastasize to the bones, spine inclusive.[1] Autopsy studies have shown that over 30% of all patients with cancer will have spinal metastases[3],[4] with or without clinical manifestation. Furthermore, in up to 10% of patients, spinal metastases are the first manifestation of cancer.[5],[6],[7] We are likely to see an increasing burden of spinal metastases in our practice. This is due to the global trend of increasing cancer survival with the advent of modern treatment modalities such as immunotherapy, targeted therapy, and stereotactic radiosurgery.[1],[8]
Metastatic spinal cord tumors typically present with back pain radiating to the lower limbs. The pain sometimes has a band/belt-like dermatomal pattern. Other symptoms may include progressive neurological deficits, ranging from weakness to absolute inability to move the limb(s). Somatosensory symptoms such as paresthesia, hyperalgesia, and sensory loss are also seen. Bladder and fecal incontinence are usually late clinical features. As a result, spinal metastases are treated as oncological emergencies to halt progression and prevent the development of these symptoms.
This article presents a 9-year review of patients treated for secondary spinal malignancies in our radiation treatment center located at a large and regionally important teaching hospital in Ibadan, the largest city in South Western Nigeria.
Materials and Methods | |  |
The study was carried out in the Radiation Oncology Department, University College Hospital (UCH), Ibadan, Nigeria. The UCH is a large regional teaching hospital in South Western Nigeria. It was the first teaching hospital in the country and has the second, of the eight, radiation treatment center with megavoltage equipment in the country.
The records of all patients who received spinal irradiation for primary or secondary malignancies in our department between January 2007 and December 2015 were retrieved. A data extraction form was used to retrieve data from the records. The extracted data are patients' sociodemographic parameters such as age, sex, and state of residence; clinicopathologic features such as the tumor type and site of metastases; and treatment factors which include the radiation dose given and retreatment dose.
Data analysis
The data were analyzed with IBM Statistical Package for Social Sciences, Version 21.0. IBM Corp. Released 2012. Armonk, NY, USA. Means and standard deviations were determined. Age was grouped into 15–39, 40–65, and ≥65 years. Frequency distributions of age group, gender, and state of residence were carried out. Frequency tables were also generated to display the distribution of cancer-type, origin (metastatic or primary spinal), irradiated dose, spinal site involved, presence or absence of further treatment, and the dose of further treatment irradiated. An appropriate test of significance (likelihood ratio) was done. The level of significance was set at 0.05.
Results | |  |
A total of 97 patients had radiation treatment to the spine during the study period. One of the patients was excluded from our analysis because he did not complete the prescribed treatment. Male patients accounted for 69.1% of the cases and females accounted for 30.1% resulting in a male–female ratio of 2.23:1. Majority of the patients, i.e., 45.8%, were elderly, aged 65 years and above. The mean age was 59.7 ± 15.3 years, and the range was 17–87 years [Figure 1].
Most of the patients resided in Oyo State (36.5%) and Lagos State (19.8%). An overwhelming majority (91.7%) of the cases had metastatic spinal malignancies. Prostate (57.3%) and breast (18.8%) cancers accounted for the majority of the cases [Table 1]. The sarcomas seen were fibrosarcoma, chondrosarcoma, malignant peripheral nerve sheath tumor, alveolar rhabdomyosarcoma, and osteosarcoma.
Site of metastases and treatment
Most of the patients presented with spinal diseases in multiple regions and received treatment that spans different spinal regions. Of the 88 patients with metastatic spinal diseases, only 21.6% presented with diseases limited to one spinal region with 13.6% and 8% in both the lumbar and the thoracic regions, respectively. The remaining were affected in multiple spinal regions mostly involving the thoracic region. Only 2.3% of the patients had the entire spine irradiated.
The lumbar and thoracic regions again accounted for most of the primary spinal tumors treated with radiotherapy with 3 of the 8 cases (37.5%) and 1 (12.5%) in the lumbar and thoracic spine, respectively. The remainders were in the thoracolumbar (37.5%) and cervicothoracic regions (12.5%) [Table 2] and [Table 3]. | Table 3: Frequency of spinal site involvement in patients with primary spinal disease
Click here to view |
Treatment doses
Majority of the patients (90.62%) were treated using multiple fractions including 10 Gy in 2 fractions, 12 Gy in 2 fractions, 15 Gy in 3 fractions, 20 Gy in 5 fractions, 24 Gy in 6 fractions, 25 Gy in 6 fractions, and 30 Gy in 10 fractions. Nine patients (9.38%) had single-fraction treatments of either 6 Gy or 8 Gy [Table 4].
Most of the breast cancer patients (61.1%) and 83.6% of the prostate cancer patients had radiotherapy to the thoracic spine. Of the nine patients who had single-fraction treatments, five were aged 40–64 years. Most of the patients (93.2%) aged 65 years and above had multiple fraction treatments. A second wave of treatment to improve symptomatic response was administered to 13 patients (13.5%). These patients were predominantly treated with 10 Gy in multiple fractions. Only 11.1% of the breast cancer and 10.9% of prostate cancer patients had repeat treatment for persistent symptoms.
In terms of the course of radiation treatment, short course being patients who received treatment 15 Gy or less and within a week and long course being other radiation schedules not meeting the criteria for short course. Majority of the patients, i.e., 58.3%, received long-course treatment. In addition, more patients in each age grouping received long-course than short-course treatment. Within the respective age groups, more patients (47.7%) aged 65 years and above received short-course treatment compared to the other age groups. The association between age and radiation treatment course was, however, not significant (P = 0.414) [Table 5].
Discussion | |  |
The spine is an important part of the human body. It is the main skeletal support for the entire trunk and serves as an important conduit and protection for the spinal cord. The spine is composed of the bony cage formed at different levels by different types of vertebrae, blood vessels, and nerve trunks that pass through it.
The spine is frequently a site of metastatic involvement in advanced malignancies, occurring in 5%–30% of all cancer patients.[9],[10] The spine is the third most common site for cancer cells to metastasize, following the lung and the liver. This amounts to 70% of all osseous metastases.
Spinal metastases may end up with irreversible neurological sequelae if not expeditiously managed. It is, therefore, important that the clinicians have a high index of suspicion, actively search for the presence of spinal metastases, and treat it expeditiously to prevent permanent motor and sensory loss.
Our results showed a male preponderance of 69% similar to the findings by others including Boström et al.[11] The median age of all patients treated was 59.7 ± 15.3 years, and the range was 17–87 years. The median age is higher than that documented in the study cited above,[11] but this could be due to the preponderance of metastatic tumors (91.7%) in our study as compared to that study in which metastatic tumors accounted for only 11.4% as it was a study specifically done on intramedullary spinal tumors who had surgery. The patients in their study were expected to be younger (to be considered fit for surgery), and intramedullary tumors are more often than not primary tumors than metastatic.
Metastatic breast and prostate cancers were the most common in our study. This is in keeping with many studies where the highest incidence of metastatic spinal disease was from these organs.[12],[13],[14],[15],[16],[17],[18] The high incidence of prostate cancer in our series may be due to the higher incidence of males seen during the period.
Metastatic cancer to the spine of unknown origin or primary has been documented to account for 3%–20% of metastatic spinal cord compression (MSCC).[5],[12],[13],[14],[19] This study reported an incidence of 3 (3.4%) of MSCC whose primary sites were unknown.
About 10% of all bone and soft-tissue sarcomas occur primarily in the spine.[15] The spine is the most common site of bony metastases from soft-tissue sarcomas in other parts of the body. Sarcomas with a higher incidence of bone metastases are alveolar soft part sarcoma, dedifferentiated liposarcoma, angiosarcoma, and rhabdomyosarcoma.[20],[21] In our study, there were five cases of sarcomas, in which three were primary spinal tumors with malignant peripheral nerve sheath tumor, alveolar rhabdomyosarcoma, and fibrosarcoma as their histologies. The metastatic sarcomas in our review were chondrosarcoma and osteosarcoma.
The site of metastases is proportional to the volume or mass of bone in each region. Several authors have documented about 60%–70% of spinal metastases occurring in the thoracic spine which has a smaller ratio of spinal cord canal diameter than the other spinal segments. The lumbar spine is involved in 20%, multiple contiguous levels 10%–38%, and cervical spine in 10%.[14],[19] In our study for both primary and metastatic diseases together, the thoracic spine was involved either alone or in combination with other spinal segments in majority of the cases (76.1%). This corresponds with other studies.[14],[15],[19],[22]
Patients with metastatic prostate cancer also had majority of spinal metastases involving the thoracic spine. This differs from a similar study in Nigeria where majority of metastatic spinal cord diseases from prostate cancer occurred in the lumbar vertebrae (75%).[23]
The spine is the most common site of bony metastases from the breast.[24],[25] In our study, majority of the patients with metastatic breast cancer had thoracic spine involvement which differs from that seen by Adewuyi et al. in Asian patients in which the lumbar spine was the most common site of spinal metastases.[24]
Primary tumors of the spine are rare and most are asymptomatic; thus, their real incidence is unknown. The most common primary tumors of the spine are hemangioma and enostoses. Except for osteoblastomas and chordomas, tumors which originate from the skeleton are not seen in the spine frequently. Primary malignant tumors of the spine are the rarest type of spinal tumors.[15] There is a slight female predilection for primary spinal tumors.[26] In our study, multiple myeloma accounted for 4 (4.1%) of all cases, half of the primary tumors. Sarcomas accounted for 3 (37.5%) and ependymoma for 1 (12.5%) of the primary spinal tumors. There was an equal sex distribution in our study even when multiple myeloma was excluded.
Conclusion | |  |
This study has highlighted the varying causes of spinal tumors necessitating radiation treatment at the UCH, Ibadan, Nigeria. Due to the increasing incidence of spinal metastasis and its debilitating natural history, health workers managing malignancies, particularly breast and prostate cancers, need to have a high diagnostic index for spinal metastases. Although most of our patients received long-course treatment, shorter courses should be evaluated because of the load on our treatment facilities and the few number of such facilities in the country. This should shorten the waiting time for patients who may require this treatment to prevent the development of motor deficits.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
References | |  |
1. | Joaquim AF, Powers A, Laufer I, Bilsky MH. An update in the management of spinal metastases. Arq Neuropsiquiatr 2015;73:795-802. |
2. | |
3. | Wong DA, Fornasier VL, MacNab I. Spinal metastases: The obvious, the occult, and the impostors. Spine (Phila Pa 1976) 1990;15:1-4. |
4. | Ortiz Gómez JA. The incidence of vertebral body metastases. Int Orthop 1995;19:309-11. |
5. | Rades D, Fehlauer F, Veninga T, Stalpers LJ, Basic H, Hoskin PJ, et al. Functional outcome and survival after radiotherapy of metastatic spinal cord compression in patients with cancer of unknown primary. Int J Radiat Oncol Biol Phys 2007;67:532-7. |
6. | Delank KS, Wendtner C, Eich HT, Eysel P. The treatment of spinal metastases. Dtsch Arztebl Int 2011;108:71-9. |
7. | Rougraff BT, Kneisl JS, Simon MA. Skeletal metastases of unknown origin. A prospective study of a diagnostic strategy. J Bone Joint Surg Am 1993;75:1276-81. |
8. | Rades D, Conde AJ, Garcia R, Cacicedo J, Segedin B, Perpar A, et al. A new instrument for estimation of survival in elderly patients irradiated for metastatic spinal cord compression from breast cancer. Radiat Oncol 2015;10:173. |
9. | |
10. | Bilsky MH, Lis E, Raizer J, Lee H, Boland P. The diagnosis and treatment of metastatic spinal tumor. Oncologist 1999;4:459-69. |
11. | Boström A, Kanther NC, Grote A, Boström J. Management and outcome in adult intramedullary spinal cord tumours: A 20-year single institution experience. BMC Res Notes 2014;7:908. |
12. | Rades D, Blach M, Nerreter V, Bremer M, Karstens JH. Metastatic spinal cord compression. Influence of time between onset of motoric deficits and start of irradiation on therapeutic effect. Strahlenther Onkol 1999;175:378-81. |
13. | Katagiri H, Takahashi M, Inagaki J, Kobayashi H, Sugiura H, Yamamura S, et al. Clinical results of nonsurgical treatment for spinal metastases. Int J Radiat Oncol Biol Phys 1998;42:1127-32. |
14. | Popoola AO, Igwilo I, Sowunmi A, Ketiku K, Duncan KJ. Analysis of malignant spinal cord compression patients treated in a radiotherapy centre. Sch J Appl Med Sci 2013;1:906-10. |
15. | Ciftdemir M, Kaya M, Selcuk E, Yalniz E. Tumors of the spine. World J Orthop 2016;7:109-16. |
16. | Maranzano E, Latini P, Perrucci E, Beneventi S, Lupattelli M, Corgna E. Short-course radiotherapy (8 Gy x 2) in metastatic spinal cord compression: An effective and feasible treatment. Int J Radiat Oncol Biol Phys 1997;38:1037-44. |
17. | Sioutos PJ, Arbit E, Meshulam CF, Galicich JH. Spinal metastases from solid tumors. Analysis of factors affecting survival. Cancer 1995;76:1453-9. |
18. | Dawotola DA, Odigie VI, Yusufu LM, Adamu A, Abur P, Jimoh AO, et al. External beam radiotherapy in metastatic bone pain from solid tumours in Zaria Nigeria. Niger J Surg 2011;17:11-4. [Full text] |
19. | Maranzano E, Latini P. Effectiveness of radiation therapy without surgery in metastatic spinal cord compression: Final results from a prospective trial. Int J Radiat Oncol Biol Phys 1995;32:959-67. |
20. | Vincenzi B, Frezza AM, Schiavon G, Santini D, Dileo P, Silletta M, et al. Bone metastases in soft tissue sarcoma: A survey of natural history, prognostic value and treatment options. Clin Sarcoma Res 2013;3:6. |
21. | Yoshikawa H, Ueda T, Mori S, Araki N, Kuratsu S, Uchida A, et al. Skeletal metastases from soft-tissue sarcomas. Incidence, patterns, and radiological features. J Bone Joint Surg Br 1997;79:548-52. |
22. | Schiff D, O'Neill BP. Intramedullary spinal cord metastases: Clinical features and treatment outcome. Neurology 1996;47:906-12. |
23. | Okeke LI, Ikuerowo SO, Popoola AA, Shittu OB, Olapade-Olaopa EO. Clinical presentation and outcome of management of patients with symptomatic spinal metastasis from prostate cancer: A five-year experience. Afr J Urol 2006;12:134-8. |
24. | Adewuyi SA, Chom ND, Humera M, Samaila MOA. Pattern of skeletal metastases from breast cancer in an Asian population. Niger J Surg Res 2006;8:128-31. |
25. | Popoola AO, Igwilo AI, Sowunmi A, Ketiku KK, Duncan KJ, Hou N, et al. Pattern of bone metastasis in breast cancer patients at a radiotherapy facility in Lagos. Br J Med Med Res 2014;4:843. |
26. | Wilartratsami S, Muangsomboon S, Benjarassameroj S, Phimolsarnti R, Chavasiri C, Luksanapruksa P. Prevalence of primary spinal tumors: 15-year data from Siriraj Hospital. J Med Assoc Thai 2014;97 Suppl 9:S83-7. |
[Figure 1]
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5]
|